-+ 0.00%
-+ 0.00%
-+ 0.00%
MEDICENNA REPORTS MORE THAN DOUBLING OF MEDIAN OVERALL SURVIVAL IN GLIOBLASTOMA PATIENTS WITH UNRESECTABLE RECURRENT IDH-WT TUMORS FOLLOWING ONE TREATMENT WITH BIZAXOFUSP VERSUS A MATCHED EXTERNAL CONTROL AT SNO 2026
Share

Please log in to view news

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending